D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Patients with neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO) often face challenges due to the ...

The leaking makes your retina swell, which hampers the work of your macula, the special, sensitive part that gives you sharp vision. To treat DME, your doctor may use drugs that are injected into ...

Rezolute has done well to continue to advance its lead drug from its pipeline, ersodetug. Click here to see why RZLT stock is ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

It is being developed as an eye drop to treat the retina to offer a non-invasive treatment alternative for diabetic macular edema (DME). This route of administration enables easy access to ...

Retina World Congress 2025 unites global retina experts in Fort Lauderdale to explore cutting-edge research, surgical ...

The primary treatment for DME includes intravitreal injections, where the eye is numbed with drops before injecting ...

Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ... (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

“This milestone validates the potential of 4D-150 to address the significant unmet needs of patients with DME, a second large market retinal vascular disease indication after wet age-related mac ...

The presentation of the DME AWARE Delphi Study interim results will highlight key areas of consensus on unmet needs in DME patient management among leading global experts. Further insights from Stage ...